About Us
- Lighthouse BioPartners was founded in the Spring of 2015
- Offices in Bradenton, Florida and Cary, North Carolina
- We have large and small pharma operational experience and are registered investment bankers
- Our focus is on business development advisory, including:
- in-licensing/buyside
- out-licensing/sellside
- scientific/partnership collaborations
- raising capital to advance our clients’ development programs
- Expertise working with large pharma, specialty pharma, diagnostics/devices and biotech
- Our clients include companies at all stages of development, from preclinical to commercial stage
- We work diligently toward a successful transaction, including all aspects of a licensing or financing process:
- preparation of materials and presentations
- outreach strategy and execution
- due diligence, including managing dataroom
- negotiation of deal terms
- transaction execution
- Allergy/Immunology
- Anti-infectives
- Cardiovascular
- CNS/Neurology
- Dermatology
- Diabetes/Metabolic
- Diagnostics/Devices
- Gastroenterology
- Gene therapy
- Hematology
- Men’s Health
- Nephrology
- Oncology/Immuno-therapy
- Orphan/Rare Diseases
- Ophthalmology
- Pediatrics
- Respiratory
- Rheumatology
- Urology
- Vaccines
- Women’s Health
Meet Us at These Upcoming Conferences
BIO International
June 5-8, 2023
Boston, MA
Bio-Europe, Fall
November 6-8, 2023
Munich, Germany
Our Team
Steven L. Levine, M.B.A.
Partner
30+ years experience in biopharma including Hybritech, Abbott, J&J and GSK with roles spanning R&D, sales, commercial analysis, marketing, and business development. Advisory work on a number of transactions including M&A, licensing and financing. MBA, University of Michigan. Registered representative with M&A Securities Group, Inc.
David J. Tomasso, M.B.A.
Partner
30+ years experience in business development, financial evaluation and analysis, sales, marketing and manufacturing. Previous experience with Merck, King, Halozyme, Ratio, and Genprex. MBA from Columbia University. Registered representative with M&A Securities Group, Inc.
Transactions
iX Biopharma
Exclusive license of proprietary sublingual ketamine
November 2021
Scioto Biosciences
Series B Investment from Genome & Company
Up to $26.5 Million
August 2020
Undisclosed
License of rights to pain product
November 2016
XOMA
Divestiture of CMC Biologics Manufacturing Facility to Agenus
November 2015
Undisclosed
License of rights to develop and commercialize pain product
September 2015
Immedica
Acquired Novartis Ophthalmology Products for Europe
October 2019
Pulmokine
License of worldwide rights to its inhaled PDGFR inhibitor for PAH and other portfolio programs to Gossamer Bio.
Up to $303 million + Tiered Royalty
October 2017
PhosImmune
Acquired by Agenus
December 2015
XOMA
Divestiture of Biodefense Program to Nanotherapeutics
November 2015
Contact Us
The principals of Lighthouse BioPartners are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer. Member FINRA/SIPC. 4151 N. Mulberry Drive, Suite 252 Kansas City, MO 64116. The testimonials presented here do not guarantee future performance or success.
–—
Copyright © 2023 Lighthouse BioPartners, LLC. All Rights Reserved.